|
Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL) Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL) conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL) Clinical research trials and Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL) medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL). Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL) Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL) clinical trial. Subjects often receive the most expert healthcare possible for their Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL) condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL)  Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL)
Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL)
For Condition: Lymphoma, Low-Grade,Non-Hodgkin's Lymphoma,Lymphoma, B-Cell
Status: Recruiting
Sponsor(s): Ligand Pharmaceuticals ,
Synopsis: The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Confirmed diagnosis of low-grade B-cell NHL whose tumor cells express CD25 - Must have received 2-5 prior therapies, one of which was a monoclonal antibody - NHL that can be measured in two dimensions (length x width) - Patient must be in good general health - No liver or kidney disease or serious heart problems - No NHL therapy, radiation or chemotherapy, or use of other study drugs within a month of beginning this study - Female patients cannot be pregnant and must use birth control during the course of the study and for three weeks after the study ends
Total Enrollment: 64
Location and Contact Information:
Overall Study Official:
GordonBray, Study Director, Ligand Pharmaceuticals
Hematology and Oncology Services *Recruiting*
Metairie, Louisiana, 70006
United States
Recruiting
Central Baptist Hospital *Recruiting*
Lexington, Kentucky, 40503
United States
Recruiting
Additional Information:
Study ID Numbers: L4389-30;
Study Start Date:
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00051025
Other Lymphoma, B-Cell Studies:
1. Phase II Study of Proteasome Inhibitor PS-341 For Patients With Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
2. Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
3. Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL)
4. Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG
5. A Safety/Efficacy Study of SGN-30 (Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies
Related Studies:
Other Lymphoma, B-Cell Clinical Trials
Other Kentucky Clinical Trials
Other Lexington Clinical Trials
Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL)
|
|
|
|
|
|
|
|
